Pfizer Inc. has filed its Specialized Disclosure Report (Form SD) with the United States Securities and Exchange Commission (SEC) for the reporting period from January 1 to December 31, 2023. The filing, made under Rule 13p-1 of the Securities Exchange Act of 1934, includes a Conflict Minerals Report as an exhibit, which is also publicly available on Pfizer's website. The report details information regarding the presence of conflict minerals such as tantalum, tungsten, tin, and gold, which may be contained in Pfizer's in-scope products. These minerals are sourced from recycled or scrap sources. The Conflict Minerals Report is incorporated by reference into the Form SD. No disclosures were required under Item 2.01 for Resource Extraction Issuer Disclosure, as it was not applicable. The Form SD was signed by Douglas M. Lankler, an authorized representative of Pfizer Inc., on May 31, 2024.

Pfizer Inc. has filed its Specialized Disclosure Report (Form SD) with the United States Securities and Exchange Commission (SEC) for the reporting period from January 1 to December 31, 2023. The filing, made under Rule 13p-1 of the Securities Exchange Act of 1934, includes a Conflict Minerals Report as an exhibit, which is also publicly available on Pfizer's website. The report details information regarding the presence of conflict minerals such as tantalum, tungsten, tin, and gold, which may be contained in Pfizer's in-scope products. These minerals are sourced from recycled or scrap sources. The Conflict Minerals Report is incorporated by reference into the Form SD. No disclosures were required under Item 2.01 for Resource Extraction Issuer Disclosure, as it was not applicable. The Form SD was signed by Douglas M. Lankler, an authorized representative of Pfizer Inc., on May 31, 2024.